Galmed Pharmaceuticals Ltd. filed its Form 6-K, detailing financial results for the three months ended March 31, 2024, showing a net loss of $1.3 million, down from $1.8 million in the same period last year. The company’s cash and equivalents decreased to $1.5 million from $2.8 million, highlighting ongoing financial challenges.